CN Patent

CN116171164A — Glp-1/gip双重激动剂

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2023-05-26 · 3y expired

What this patent protects

本发明涉及长效胰高血糖素样肽‑1和人葡萄糖依赖性促胰岛素多肽(GIP)双重激动剂多肽，其可以用于治疗2型糖尿病(T2D)、伴有肥胖症的糖尿病、肥胖症和高脂血症。

USPTO Abstract

本发明涉及长效胰高血糖素样肽‑1和人葡萄糖依赖性促胰岛素多肽(GIP)双重激动剂多肽，其可以用于治疗2型糖尿病(T2D)、伴有肥胖症的糖尿病、肥胖症和高脂血症。

Drugs covered by this patent

Patent Metadata

Patent number
CN116171164A
Jurisdiction
CN
Classification
—
Expires
2023-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.